
in patients with symptoms of ⬍14 days of duration would
seem fairly secure. Although a benefit in patients with a
duration of symptoms of ⬎14 days cannot be excluded,
chronic thrombosis does appear to be associated with inferior results,16 and the relative benefits vs risks in such
patients should be considered on an individualized basis.
Given the options available for the treatment of acute
iliofemoral DVT, it is unlikely that all